HEALTHTHE HILL
FDA panel recommends mRNA flu vaccine for older adults
An FDA advisory panel unanimously recommended Moderna’s mRNA-based flu vaccine, mFlusiva, for approval in adults aged 50-64 and 65+. The panel voted 9-0 that the benefits outweigh the risks for the vaccine.
Mentioned
Related Signal
Adjacent reporting
- FDA panel recommends Moderna’s mRNA flu shot for older adults
- STAT+: FDA advisory panel endorses Moderna mRNA flu vaccine that was subject of controversy
- FDA panel backs first-of-its-kind flu vaccine using mRNA technology
- FDA panel considers a first-of-its-kind flu vaccine using mRNA technology
- FDA panel considers a first-of-its-kind flu vaccine using mRNA technology